

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Animal Healthcare Ltd.

中國動物保健品有限公司*

(Incorporated in Bermuda with limited liability)

(Hong Kong Stock code: 0940)

**(1) UPDATE ON PROGRESS OF FULFILMENT OF RESUMPTION
CONDITIONS**

**(2) UPDATE ON RECENT DEVELOPMENT OF SUSPENSION OF
TRADING**

This announcement is made by China Animal Healthcare Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board of Directors of the Company hereby updates the shareholders of the Company on the current progress of the Company towards fulfilling the resumption conditions imposed by the Stock Exchange and the recent developments with respect to the suspension of trading in the shares of the Company.

Reference is made to the announcements of the Company dated 14 November 2017, 20 November 2017, 7 May 2018, 1 August 2018, 18 October 2018 and 7 November 2018 in relation to, among other things, the suspension of trading of the shares of the Company.

Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as defined in the above announcements.

(1) UPDATE ON PROGRESS OF FULFILMENT OF RESUMPTION CONDITIONS

In respect of publication of the outstanding financial results, the Company and its auditors, HLB Hodgson Impey Cheng Limited, have been undertaking the necessary actions to finalize and publish the interim results of the Company and its subsidiaries for the six months ended 30 June 2017, (ii) the annual results of the Company and its subsidiaries for the year ended 31 December 2017 and (iii) the interim results of the Company and its subsidiaries for the six months ended 30 June 2018 (the “**Outstanding Financial Results**”). While the Company is not able to estimate the exact timeframe for publication of the Outstanding Financial Results at this stage, the Company will make further announcements to update and inform the shareholders and potential investor of the Company of the progress.

As announced on 14 November 2017, the Company has fully completed the internal control review and is of the view that the 3rd Resumption Condition has been duly complied with.

The Board of Directors of the Company will continue to use their best efforts to resolve the remaining issues under the Resumption Conditions, and shall continue to safeguard the interests of the Company and its shareholders as a whole.

(2) UPDATES ON RECENT DEVELOPMENT OF SUSPENSION OF TRADING

On 5 October 2018, the Company received a facsimile from the Stock Exchange notifying the Company that the Listing (Review) Committee decided to uphold the LC’s Decision to commence the procedures under Rule 6.10 of the Listing Rules to cancel the Company’s listing on the ground that the Company is no longer suitable for listing (the “**Review Committee’s Decision**”).

Pursuant to the said facsimile, the Company will have a period of 6 months from the date of announcement to be published by the Listing Department to remedy the matters that have rendered it unsuitable for listing, failing which the Listing Department will make a recommendation to the Listing Committee to proceed with the cancellation of the Company's Listing.

Notwithstanding that Review Committee's Decision above, the Board would like to assure its shareholders that the Company has all along been and will continue making its best endeavours and taking active and prompt steps to fulfil the resumption conditions imposed by the Stock Exchange and address other concerns of the Stock Exchange, including but not limited to the publication of the Outstanding Financial Results.

Further announcement will be made by the Company to inform the shareholders and potential investor of the Company of the development of this matter as and when appropriate in accordance with the Listing Rules.

CONTINUAL SUSPENSION OF TRADING

At the request of the Company, the shares of the Company have been suspended from trading on the Stock Exchange from 9 a.m. on 30 March 2015. Trading in the Company's shares will continue to suspend until further notice.

Shareholders and potential investors are advised to exercise caution when dealing in the Shares.

By order of the Board
China Animal Healthcare Ltd.
Wang Yongwei
Chairman, Executive Director

Hong Kong, 11 February 2019

As at the date of announcement, the executive Director is Mr. Wang Yongwei.

** For identification purpose only*